Articles by Tom von Gunden
-
Does Drug Discovery Anticipate Delivery?
10/28/2026
In this article, Chief Editor Tom von Gunden considers the relationship between drug discovery and drug delivery. His commentary includes reflections on conversations and encounters from the Discovery & Development US conference, where formulation and delivery topics were also in the air and on the agenda.
-
How Risk Underpins Drug Delivery Development With Suttons Creek's Alex Spivak
10/27/2026
Videocast host Tom von Gunden and Suttons Creek Principal Consultant Alex Spivak discuss the foundational importance of risk management in the development of a device-delivered drug product. Tracing the product development lifecycle, they illuminate key inflection points, such as user requirements, hazards analysis, design inputs, design freeze, and design verification testing. They also discuss key regulatory guidance, including 21 CFR Part 4 for combination products.
-
Enabling In Vivo CAR-T Therapy Delivery With Vyriad's Stephen Russell
10/20/2026
In this episode of Sit and Deliver, host Tom von Gunden and Vyriad Co-Founder and CSO Stephen Russell discuss in vivo delivery of CAR-T cell therapies as an alternative to ex vivo approaches requiring cell harvesting and reinfusion. Russell describes lentiviral vectors delivered in vivo to trigger T cells to attack cancerous tumors. He outlines benefits of the approach, including increased patient convenience, as well as reduced costs across the healthcare ecosystem.
-
The Resurgence Of Fervor For Oral Delivery
10/7/2026
In this article, Chief Editor Tom von Gunden reports on the science and technology boosting the rise in attention to oral methods for advanced drug and biologics delivery. The insights he illuminates include innovative approaches to increasing permeability, solubility, and bioavailability, as well as expanding the types and sizes of therapeutic payloads formulated for oral administration.
-
How Formulation Scientists View Drug Delivery With Yogesh Bachhav
9/28/2026
Videocast host Tom von Gunden talks with Yogeshwar Bachhav, CMC consultant for AiCuris AG Germany, about scientific and technical considerations in the alignment of drug formulations with routes of administration and related delivery systems during product development. Topic coverage includes delivery considerations related to viscosity, permeability, solubility, safety, usability, packaging, and supply chain.
-
Personalizing LNP-Delivered RNA Payloads At Scale With Acuitas' Ying Tam
9/21/2026
In this episode of Supplier Horizons, host Tom von Gunden discusses with Chief Scientific Officer Ying Tam from LNP platform developer Acuitas Therapeutics the use of lipid nanoparticles as RNA delivery vehicles across an expanding range of targetable indications, including outside the liver. Among the advances discussed are delivering CAR-T therapies in vivo, loading personalized therapeutic payloads into preformed vesicles, and maintaining RNA stability throughout targeted cellular delivery.
-
Delivery Considerations For Ophthalmic Targets With Sanner's Rob Henson
9/10/2026
Rob Henson, Director of Design and Engineering for Sanner US, joins Supplier Horizons host Tom von Gunden to discuss injection devices and other delivery technologies for treating chronic ophthalmic conditions. The topic coverage includes patient safety, device ease-of-use, particulate and endotoxin control, and dose size management in both solid and liquid formulations.
-
Investigating Immunogenicity In Sub-Q Delivery With The Subcutaneous Consortium
8/28/2026
In this episode of In Combination, representatives from the Immunogenicity subteam within industry association The Subcutaneous Drug Development & Delivery Consortium join host Tom von Gunden to discuss the role and impact of immunogenicity in biotherapeutics product development for sub-Q delivery. Members of the subteam describe the group’s focuses on degrees of desired or acceptable immunogenic response, as well as on industry harmonization of assays employed in preclinical and clinical modeling.
-
Managing Logistics For Personalized Therapies With Cryoport Systems' Dominic Clarke
8/21/2026
In this episode of Supplier Horizons, Dominic Clarke, VP of Technical Operations at specialty supply chain provider Cryoport Systems, joins host Tom von Gunden to discuss logistics practices and challenges in getting CGTs (cell and gene therapies) and other advanced biologics to patients. Using autologous CAR-T therapies as primary example, Clarke describes needs and advances in the collection, transport, manufacturing, cold chain storage, and delivery of personalized medicines.
-
Inquiries In Inhalation, Part 2: Having A Nose For Innovation
8/19/2026
In this follow-up article, Chief Editor Tom von Gunden extends his Part 1 discussion of therapeutic targets for inhaled drugs and biologics into specific aspects of delivery innovation. Among the key considerations are particle engineering, device usability, and the coordination across the ecosystem of inhalation delivery design, development, and distribution. The coverage of advances in device technologies includes inhalers, nebulizers, and nasal sprays.